Hepatitis C virus NS5A protein — Drug Target

All drugs that target Hepatitis C virus NS5A protein — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

NS5A inhibitor · Direct-acting antiviral (DAA); NS5A inhibitor

Phase 3 pipeline (1)

• BMS-790052 (Daclatasvir) · Bristol-Myers Squibb · NS5A inhibitor · Virology/Infectious Disease
  Daclatasvir inhibits the hepatitis C virus NS5A protein, blocking viral replication and spread.